BR9806989A - Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero. - Google Patents

Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.

Info

Publication number
BR9806989A
BR9806989A BR9806989-6A BR9806989A BR9806989A BR 9806989 A BR9806989 A BR 9806989A BR 9806989 A BR9806989 A BR 9806989A BR 9806989 A BR9806989 A BR 9806989A
Authority
BR
Brazil
Prior art keywords
treating
epidermis
activators
mammalian individual
receptor
Prior art date
Application number
BR9806989-6A
Other languages
English (en)
Inventor
Peter M Elias
Nathan M Bass
Karen Hanley
Kenneth R Feingold
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9806989A publication Critical patent/BR9806989A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

"PROCESSO PARA TRATAR A EPIDERME OU MEMBRANA DA MUCOSA DE UM INDIVìDUO MAMìFERO TERRESTRE". Distúrbios da pele e membranas da mucosa que tem uma barreira epidérmica perturbada ou disfuncional são tratados ou evitados por aplicação tópica de compostos que são ou ativadores do receptor X de farnesóide, ativadores de receptor ativado por proliferador de peroxissoma, e ativadores de oxiesterol de receptor LXR. Os mesmos compostos também são efetivos para tratar distúrbios de diferenciação e proliferação epidérmica.
BR9806989-6A 1997-01-24 1998-01-22 Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero. BR9806989A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78897397A 1997-01-24 1997-01-24
PCT/US1998/001276 WO1998032444A1 (en) 1997-01-24 1998-01-22 USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION

Publications (1)

Publication Number Publication Date
BR9806989A true BR9806989A (pt) 2000-03-14

Family

ID=25146166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806989-6A BR9806989A (pt) 1997-01-24 1998-01-22 Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.

Country Status (10)

Country Link
US (2) US6184215B1 (pt)
EP (1) EP1019059A4 (pt)
JP (2) JP2001509165A (pt)
CN (1) CN1248916A (pt)
AU (1) AU5928898A (pt)
BR (1) BR9806989A (pt)
CA (1) CA2278123A1 (pt)
HU (1) HUP0001938A3 (pt)
PL (1) PL334840A1 (pt)
WO (1) WO1998032444A1 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760362B1 (fr) * 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
GB9804861D0 (en) 1998-03-06 1998-04-29 Res Inst Medicine Chem Chemical compounds
JP2002528721A (ja) * 1998-10-23 2002-09-03 グラクソ グループ リミテッド 核内受容体のリガンド用のアッセイ
JP4194196B2 (ja) * 1999-02-22 2008-12-10 花王株式会社 浴用剤組成物
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
EP1161412A1 (en) * 1999-03-16 2001-12-12 Glaxo Group Limited Nuclear receptor arylating compounds
US6284802B1 (en) 1999-04-19 2001-09-04 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue
US6444647B1 (en) 1999-04-19 2002-09-03 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
MXPA01011070A (es) 1999-04-30 2003-06-30 Arch Dev Corp Derivados de esteroides.
US6365138B1 (en) * 2000-04-07 2002-04-02 The Regents Of The University Of California Compositions for metabolic protection and repair of lips
EP1331934B1 (de) * 2000-11-09 2006-03-29 Phenion GmbH & Co KG Ppar-alpha,beta-aktivatoren zur behandlung von alopecia areata und vitiligo
WO2002083131A1 (en) * 2001-04-13 2002-10-24 The Regents Of The University Of California Activators and ligands of ppar-beta/delta for the treatment of skin conditions
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
GB0114848D0 (en) 2001-06-18 2001-08-08 Unilever Plc Antiperspirant or deodorant compositions
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
WO2003030857A1 (en) * 2001-10-04 2003-04-17 Unilever Plc Enhancing epidermal barrier development in skin
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ATE521599T1 (de) 2001-12-21 2011-09-15 X Ceptor Therapeutics Inc Heterocyclische modulatoren von nukleären rezeptoren
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
JP2006503819A (ja) * 2002-08-29 2006-02-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨形成を増進するための作用剤および方法
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
FR2847467B1 (fr) * 2002-11-25 2006-05-26 Oreal UTILISATION D'UN AGENT MODULATEUR DE L'ACTIVITE DE L'OXYSTEROL 7alpha-HYDROXYLASE POUR LE TRAITEMENT COSMETIQUE DE DESORDRES CUTANES
DE60335911D1 (de) * 2002-12-20 2011-03-10 Daiichi Sankyo Co Ltd Isochinolinonderivate und deren verwendung als medikamente
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
GB0311815D0 (en) * 2003-05-22 2003-06-25 Unilever Plc Skin treatments
US9532994B2 (en) * 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
FR2863610B1 (fr) * 2003-12-11 2006-01-20 Galderma Res & Dev NOUVEAUX COMPOSES MODULATEURS DES RECEPTEURS DE TYPE PPARs ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
CA2545767A1 (en) * 2003-12-11 2005-06-30 Galderma Research & Development, S.N.C. Novel compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
WO2005101011A2 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
WO2006114073A1 (de) * 2005-04-23 2006-11-02 Ixetic Mac Gmbh Axialkolbenmaschine
US7618956B2 (en) * 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
WO2007002559A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
AU2006284650A1 (en) * 2005-09-02 2007-03-08 The Regents Of The University Of California Osteogenic and anti-adipogenic oxysterols
KR100659138B1 (ko) * 2005-09-16 2006-12-19 (주)아모레퍼시픽 유효성분으로 갈로카테킨 갈레이트를 함유하는 보습용피부외용제 조성물
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US9670244B2 (en) * 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2007106912A2 (en) * 2006-03-16 2007-09-20 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peroxisome-proliferator activated receptor-alpha agonists for organ preservation
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20100048944A1 (en) * 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
WO2008082520A2 (en) 2006-12-19 2008-07-10 The Regents Of The University Of California Inhibition of ppar gamma expression by specific osteogenic oxysterols
EP2146724A2 (en) * 2007-03-16 2010-01-27 The Regent of the University of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090082314A1 (en) * 2007-06-29 2009-03-26 The Provost Fellows And Scholars Of The College Of The Targeting Prodrugs for the Treatment of Gastrointestinal Diseases
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
EP2231164A1 (en) * 2007-12-03 2010-09-29 The Regents of the University of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2093222A1 (en) * 2008-02-22 2009-08-26 Newbiotechnic, S.A. Polyisoprenoid epoxides useful for decreasing cholesterol and/or increasing coenzyme Q biosynthesis
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EA021177B1 (ru) 2009-05-08 2015-04-30 Пронова Биофарма Норге Ас Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями
EP2435410B1 (en) 2009-05-28 2017-01-18 Exelixis Patent Company LLC Lxr modulators
CN102482315A (zh) 2009-07-29 2012-05-30 芝加哥大学 肝x受体激动剂
WO2011103175A2 (en) * 2010-02-16 2011-08-25 The Regents Of The University Of California Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
FR2958641B1 (fr) * 2010-04-08 2014-12-26 Sederma Sa Nouveaux composes de type polyterpenique, compositions cosmetiques, nutraceutiques et pharmaceutiques les contenant et utilisations dans ces domaines.
MX2012014801A (es) 2010-07-08 2013-01-29 Wyeth Llc Esteres de quinolina nuevos utiles para el tratamento de transtornos cutaneos.
EA028535B1 (ru) 2010-11-05 2017-11-30 Пронова Биофарма Норге Ас Способы лечения с применением липидных соединений
JP2012171924A (ja) * 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
JP6262723B2 (ja) 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
AR094941A1 (es) 2013-02-28 2015-09-09 Olaf Hustvedt Svein Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla
WO2014144037A1 (en) 2013-03-15 2014-09-18 Bristol-Myers Squibb Company Lxr modulators
CA2911205A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
CA2953754A1 (en) * 2014-07-02 2016-01-07 David Lembo Oxysterols for use in the treatment and prevention of diseases caused by viruses
EA036404B1 (ru) * 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
WO2018206409A1 (en) * 2017-05-08 2018-11-15 Unilever Plc Prevention and/or treatment of inflammatory skin disease
SG11202005007VA (en) 2017-12-06 2020-06-29 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
DE3621861A1 (de) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
JP2513877B2 (ja) * 1989-03-13 1996-07-03 セレジー ファーマシューティカルズ，インコーポレイティド 皮膚疾患及び腫瘍の処理のための製剤
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
US5175190A (en) * 1991-02-15 1992-12-29 The University Of British Columbia Medium chain fatty acids of C8-10 for the treatment of skin lesions
FR2702391B1 (fr) * 1993-03-11 1995-04-28 Roussel Uclaf Nouvelles émulsions multiples, leur préparation, leur application à la préparation de compositions cosmétiques et ces compositions cosmétiques.
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs

Also Published As

Publication number Publication date
US6187814B1 (en) 2001-02-13
EP1019059A1 (en) 2000-07-19
CN1248916A (zh) 2000-03-29
PL334840A1 (en) 2000-03-27
JP2005247854A (ja) 2005-09-15
AU5928898A (en) 1998-08-18
US6184215B1 (en) 2001-02-06
HUP0001938A3 (en) 2001-09-28
JP2001509165A (ja) 2001-07-10
WO1998032444A1 (en) 1998-07-30
EP1019059A4 (en) 2004-01-14
CA2278123A1 (en) 1998-07-30
HUP0001938A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
BR9806989A (pt) Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.
BR0212142A (pt) Método e sistema para tratamento de acne
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
DE60115618D1 (de) Verwendung von kosmetische und pharmazeutische zubereitungen enthaltend 2-decarboxy-2-phosphino prostaglandinderivate
BR9502337A (pt) Uso de uma água composiçao cosmética e/ou dermatológica uso de uma composiçao e processo para o tratamento cosmético da acne rugas e/ou finas linhas da pele
ATE277588T1 (de) Sprühbare zubereitungen enthaltend dispernierten pulvers sowie dessen anwendungsverfahren
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
ES2119897T3 (es) Procedimiento y composicion para el cuidado de la piel.
ATE552891T1 (de) Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung
BR9702541A (pt) Composição cosmética e/ou dermatológica utilização da composição e processo para tratamento não-terapêutico cosmético
FI972580A0 (fi) Valmisteita ja menetelmiä ihoärsytyksen vähentämiseksi
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR9810062A (pt) Composição cosmética contendo um agente alvejante, bem como uso de uma fonte de água em combinação com a mesma
BR0309890A (pt) Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação
DE59703511D1 (de) Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
UY23909A1 (es) Procedimiento para la preparacion de 6- derivados sustitutivos del acido micofenolico
BR9708460A (pt) Composto, composição farmacêutica e processo para prevenir ou tratar uma condição patológica em um humano ou animal não-humano.
BR9611587A (pt) Processo e composição para tratamento da pele deseres humanos e preparação tópica para aplicação à pele.
BR9806925A (pt) Emulsão óleo-em-água, uso de uma emusão óleo-em-água, composição cosmética e/ou dermatológica, processo de tratamento cosmético e uso dos derivados de 1,3,5-triazina
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
BR0206514A (pt) Composto, método de tratamento de um ser humano ou animal que sofre de enxaqueca, uso do composto, composição farmacêutica, e, processo para preparar um composto
ATE245452T1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
RU95103892A (ru) Композиция топического нанесения для стимулирования роста волос и/или замедления их выпадения, способ косметического лечения волос, применение производного альфа -пирона для получения композиции

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ,

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36O DA LPI